The only one from that marketing pitch that hospitals really watch is length of stay, because there are diminishing marginal returns the longer a patient stays in a single visit. Also, not listed is avoiding readmission from the same procedure because medicare will not pay. Most of those items are patient care issues and are good for marketing but have no bearing on cost/reimbursement. Infection rate is difficult to tie to something like less incision sites and thus not usually considered. Same for blood loss. Both of those are usually more strongly related to the surgeon and not correlated to other variables. Most payors will not reimburse disposables/reposables, which is 100%of the supplies directly attributable to the use of the robot. I think the biggest sell to administration is a lower cost to operate robot. That in mind, txrc will be a competitor from a cost perspective, despite being an inferior clinical offering. Same with flexdex. If surgeons say they can use those for $800 a procedure, instead of a costly robot, admin would jump all over that. Big cost savings.
News 
Market Data 
Discover 
